Detection of the administration of human erythropoietin (HuEPO) to canines.
نویسندگان
چکیده
Recombinant human erythropoietin (rHuEPO) doping is prohibited in animal (canine and equine) sport. The effectiveness of a range of immunoassay screening methods for the detection of rHuEPO in canine urine was evaluated. The excretion profiles following rHuEPO administration to dogs were investigated. The presence of rHuEPO in postadministration samples was confirmed using the World Anti-Doping Agency (WADA)-approved isoelectric focusing immunoblotting confirmatory technique. Following the administration study, a screening program involving approximately 6000 greyhound sport (mostly racing) samples was undertaken for rHuEPO. This resulted in the detection of the first rHuEPO positives in the world of canine or equine sport. In an additional case, endogenous HuEPO was detected in a sample submitted as greyhound urine. It was determined that this arose from the submission to control stewards, as greyhound urine, of a substance that was, in fact, human urine. This was a particularly welcome development as definitive confirmatory evidence of such sample switching can be difficult to obtain in the case of greyhounds.
منابع مشابه
Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis.
BACKGROUND AND OBJECTIVES The detection of recombinant human erythropoietin (r-HuEPO) abuse by athletes remains problematic. The main aim of this study was to demonstrate that the five indirect markers of altered erythropoiesis identified in our earlier work were reliable evidence of current or recently discontinued r-HuEPO use. A subsidiary aim was to refine weightings of the five markers in t...
متن کاملRECOMBINANT HUMAN ERYTHROPO IETIN IN THE TRE ATMENT OF ANEMIA IN CHILDREN
We have used recombinant human erythropoietin (r-HuEPO) in children with chronic renal failure. There was significant improvement in anemia and wellbeing, along with regression of left ventricular mass and no change in the rate of decline of renal function. It is safe and effective in the pre-dialysis as well as the hemodialysis period. Considering the benefits of r-HuEPO, transplantation i...
متن کاملOptimizing the Erythropoietin Use in Chronic Renal Failure Patients
Thirteen years have passed since the first patient with end stage renal disease received recombinant human erythropoietin (r-HuEPO). During this time many thousands of patients have been receiving r-HuEPO, and the knowledge of how to use EPO successfully and how to avoid adverse effects has been achieved. However, because of the costs of r-HuEPO, a great number of patients still lack beneficial...
متن کاملWeekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
R ecombinant human enythropoietin (r-HuEPO) is widely used to treat the anemia of chronic renal failure. Standard therapy is to administer r-HuEPO at doses of 50 to 1 50 U/kg iv three times a week after hemodiabysis treatment (1-3). This route of administration and dosing schedule are based on pharmacokmnetic studies that demonstrate that the half-life for an iv dose is approximately 6 to 9 h (...
متن کاملRecombinant human erythropoietin: 10 years of clinical experience.
The need for a renewable source of erythropoietin to treat the anaemia of chronic renal failure was first recognized in the 1960s, but cloning and expression of the human gene was not achieved until 1983. Clinical testing of recombinant human erythropoietin (r-HuEPO) began in 1985, leading to the first licence as a therapeutic agent in 1988. The first clinical trials showed that an intravenous ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of analytical toxicology
دوره 30 9 شماره
صفحات -
تاریخ انتشار 2006